INNOVIVA

Innoviva Specialty Therapeutics secures exclusive U.S. distribution and licensing rights for Zevtera® (ceftobiprole) from Basilea Pharmaceutica. The FDA-approved antibiotic is the only MRSA cephalosporin for treating adult patients with Staphylococcus aureus bloodstream infections and endocarditis. The agreement includes a $4 million upfront payment plus tiered royalties and sales milestones, with a planned commercial launch in mid-2025.

Indian drugmakers urged to focus R&D on antibacterial and anti-fungal medicines, aligning with public health needs, especially for LMICs. ATMF highlights the global shortfall in developing replacement antibiotics against AMR, stressing the need for early access programs and broader registrations to combat superbugs and save lives.